Influence of low-dose colchicine on coronary microcalcification activity in patients with diffuse coronary artery disease undergoing coronary artery bypass grafting: protocol for single-centre randomised open-label blinded-endpoint trial (the COL-CABG trial) Authors: Mingxin Gao, Xiangzhi Kong, Xinran Xu, Wenjing Zhao, Qin Li, Jie Gao, Yuyong Liu, Yupeng Liu, Yang Yu, Xiaoli Zhang, Haiyang Li Published: 2026 ABSTRACT AbstractIntroductionCoronary artery bypass grafting (CABG) is the main method to improve myocardial ischaemia in patients with complex coronary artery stenosis. Whereas, patients with diffuse coronary artery disease (DCAD) have a high incidence of perioperative myocardial infarction (PMI) and long-term major adverse cardiovascular and cerebrovascular events (MACCEs) after CABG. The coronary microcalcification activity reflected by sodium [18F]fluoride (18F-NaF) uptake has strong predictive value for the adverse events indication after CABG, which is closely related to the coronary immunoinflammatory microenvironment. Low-dose colchicine (0.5 mg/day) was recommended by the 2024 European Society of Cardiology (ESC) guidelines for the management of chronic coronary syndromes, to be administered except statins and standard secondary prevention therapies, for the prevention of MACCEs. The effectiveness of low-dose colchicine is considered to enhance coronary plaque stability and reduce adverse events, but the mechanism is unclear. Therefore, the aim of this trial is to evaluate the effects of low-dose colchicine on coronary microcalcification activity and the incidence of MACCEs in patients with DCAD undergoing CABG.Methods and analysisThe COL-CABG trial is a single-centre, prospective, randomised, open-label, blinded-endpoint trial conducted at Beijing Anzhen Hospital, Capital Medical University. The study will prospectively enrol 108 DCAD patients with a tissue-to-background ratio (TBR) >3.6 at Beijing Anzhen Hospital from July 2026 to June 2028, and all patients are planned to undergo CABG. The patients will be randomly assigned (1:1) to (1) the colchicine group and (2) the control group. The primary endpoint is defined as the changes in coronary microcalcification activity (ΔTBR=TBR (baseline)–TBR (90 days)) at 90 days after CABG in comparison with pre-CABG. Secondary clinical outcomes include PMI within 7 days after CABG and MACCEs within 90 days after CABG. MACCEs include all-cause death, cardiogenic shock, spontaneous myocardial infarction occurring after postoperative day 7, stroke and repeat coronary revascularisation. These clinical outcomes will be interpreted as exploratory and hypothesis-generating.Ethics and disseminationThis study has been approved by the Institutional Review Board of Beijing Anzhen Hospital, Capital Medical University (approval number: 2025202x). Written informed consent will be obtained from all participants. The results will be disseminated through peer-reviewed publications and scientific conference presentations.Trial registration numberChiCTR2500111659. STRENGTHS AND LIMITATIONS OF THIS STUDY This is a prospective, single-centre, randomised open-label, blinded-endpoint trial conducted in patients with diffuse coronary artery disease undergoing coronary artery bypass grafting. This is a prospective, single-centre, randomised open-label, blinded-endpoint trial conducted in patients with diffuse coronary artery disease undergoing coronary artery bypass grafting. Serial sodium [18F]fluoride positron emission tomography/CT will be used to quantify coronary microcalcification activity at baseline and 90 days after surgery. Serial sodium [18F]fluoride positron emission tomography/CT will be used to quantify coronary microcalcification activity at baseline and 90 days after surgery. Imaging outcomes and clinical endpoints will be assessed by investigators blinded to treatment allocation. Imaging outcomes and clinical endpoints will be assessed by investigators blinded to treatment allocation. The open-label design may introduce performance bias despite blinded endpoint assessment. The open-label design may introduce performance bias despite blinded endpoint assessment. The trial is powered for the imaging endpoint rather than for clinical events, which will therefore be interpreted as exploratory outcomes. The trial is powered for the imaging endpoint rather than for clinical events, which will therefore be interpreted as exploratory outcomes. Introduction Background and rationale At coronary angiography, diffuse coronary artery disease (DCAD) is defined as a long coronary segment (≥20 mm) with angiographic irregularities in the absence of a clear focal stenosis, and accounts for 12%–30% of coronary artery disease.1 The 1-year cardiovascular mortality rate in patients with DCAD treated without surgery exceeds 30%, and the 5-year survival rate is less than 50%.2 Although coronary artery bypass grafting (CABG) can reduce the 5-year incidence rate of major adverse cardiovascular and cerebrovascular events (MACCEs) to 25% in patients with DCAD, the incidence of perioperative myocardial infarction (PMI) remains as high as 20%, and the mid- to long-term MACCEs are 2–3 times higher than in patients with coronary focal lesions.3 High-risk plaque rupture is regarded as the main reason for MACCEs in patients with complex coronary artery stenosis,4 but it is a challenge to predict the events in DCAD patients after CABG. Coronary artery microcalcification is a specific biomarker of vulnerable plaque, and its activity is correlated with coronary artery uptake of sodium [18F]fluoride (18F-NaF), which can be precisely detected by positron emission tomography/CT (PET/CT).5 The uptake of 18F-NaF by the coronary artery, which is reflected by the tissue-to-background ratio (TBR), has strong power to predict the PMI and long-term MACCEs in DCAD patients undergoing CABG.6 7 In our prospective study, we found that patients with complex coronary artery stenosis and TBR >3.6 of 18F-NaF increased the risk of MACCEs by 8.5-fold after CABG, outperforming the conventional metrics of anatomical assessment and serum markers.3 Furthermore, it was first confirmed by pathological methods in our group that coronary artery microcalcification activity is significantly correlated with high-risk plaques and an inflammatory environment, which has become a target for intervention.8 Low-dose colchicine (0.5 mg/day) was recommended as Class IIa, Level A by the 2024 European Society of Cardiology (ESC) guidelines for chronic coronary syndromes to reduce myocardial infarction, stroke and need for revascularisation in patients with chronic coronary syndrome.9 Some high-quality RCTs have validated the efficacy of low-dose colchicine in reducing the risk of cardiovascular events by 31% in patients with stable coronary artery disease (Low-Dose Colchicine 2 (LoDoCo2) trial)10 and by 23% in patients with acute infarction (Colchicine Cardiovascular Outcomes (COLCOT) trial).11 The EKSTROM (Effect of Colchicine on Progression of Known Coronary Atherosclerosis in Patients With Stable Coronary Artery Disease Compared to Placebo) trial revealed that low-dose colchicine could decrease plaque volume and high-sensitivity C reactive protein (CRP) in patients with stable coronary artery disease.12 For patients with DCAD who suffer from more complex coronary artery lesions and inflammation, we hypothesised that low-dose colchicine administration as secondary prevention therapy after CABG improves coronary microcalcification activity and reduces the incidence of MACCEs. Objectives The COL-CABG trial aims to demonstrate through a prospective, randomised, open-label, blinded endpoint (PROBE) trial the efficacy of low-dose colchicine in reducing coronary microcalcification activity and preventing early adverse events (PMI and 90-day MACCEs) following CABG in patients with DCAD. Methods Trial design The COL-CABG trial is a single-centre, prospective, randomised, open-label, blinded-endpoint trial. Treatment allocation will be open-label for participants and treating clinicians after randomisation, whereas PET/CT imaging outcomes, clinical endpoints and statistical analyses will be assessed by investigators blinded to treatment allocation. Outcome measures will be collected at 7 days and 90 days, and exploratory clinical follow-up will continue for up to 1 year after CABG. This clinical trial will be conducted in the Department of Cardiac Surgery at Beijing Anzhen Hospital, Capital Medical University. Recruitment is scheduled to begin on 1 July 2026 and is planned to be completed by 30 June 2028. The final 90-day follow-up visit is expected to be completed by 30 September 2028. Study setting Beijing Anzhen Hospital, Capital Medical University, Beijing, China. Eligibility criteria Participants will be screened according to the following inclusion and exclusion criteria. Eligibility will be confirmed independently by two experienced cardiac surgeons or interventional cardiologists before randomisation, with disagreements resolved by consensus with a third senior reviewer. Inclusion criteria Age 18–80 years. Age 18–80 years. Meet the indications for CABG according to the 2024 ESC guidelines for coronary revascularisation. Meet the indications for CABG according to the 2024 ESC guidelines for coronary revascularisation. DCAD defined at the patient level as angiographically confirmed diffuse atherosclerotic disease involving a continuous or near-continuous coronary segment of ≥20 mm in at least one major epicardial coronary artery or major branch planned for surgical revascularisation, with severe luminal stenosis of ≥75% within the diseased segment. DCAD defined at the patient level as angiographically confirmed diffuse atherosclerotic disease involving a continuous or near-continuous coronary segment of ≥20 mm in at least one major epicardial coronary artery or major branch planned for surgical revascularisation, with severe luminal stenosis of ≥75% within the diseased segment. Coronary artery uptake of TBR >3.6 on preoperative 18F-NaF PET/CT. Coronary artery uptake of TBR >3.6 on preoperative 18F-NaF PET/CT. Understand and agree to participate in the programme. Understand and agree to participate in the programme. Exclusion criteria Recent (occurring within the past 4 weeks) acute myocardial infarction. Recent (occurring within the past 4 weeks) acute myocardial infarction. Preoperative echocardiography suggesting an ejection fraction of ≤35% or severe congestive heart failure (New York Heart Association (NYHA) class IV). Preoperative echocardiography suggesting an ejection fraction of ≤35% or severe congestive heart failure (New York Heart Association (NYHA) class IV). Preoperative echocardiogram suggesting that the patient has a combination of one or more of the following valve diseases: moderate or greater stenosis/insufficiency of the aortic valve, moderate or greater stenosis/insufficiency of the mitral valve. Preoperative echocardiogram suggesting that the patient has a combination of one or more of the following valve diseases: moderate or greater stenosis/insufficiency of the aortic valve, moderate or greater stenosis/insufficiency of the mitral valve. Congenital heart diseases, including atrial and ventricular septal defects, patent ductus arteriosus, tetralogy of Fallot, foramen ovale and patent ductus arteriosus. Congenital heart diseases, including atrial and ventricular septal defects, patent ductus arteriosus, tetralogy of Fallot, foramen ovale and patent ductus arteriosus. Aortic aneurysm, aortic dissection and intramural aneurysm. Aortic aneurysm, aortic dissection and intramural aneurysm. Cirrhosis or positive serum hepatitis B surface antigen (HBsAg)/ hepatitis B e antigen (HBeAg), hepatitis C virus (HCV)-RNA or anti-HCV antibodies. Cirrhosis or positive serum hepatitis B surface antigen (HBsAg)/ hepatitis B e antigen (HBeAg), hepatitis C virus (HCV)-RNA or anti-HCV antibodies. Active malignancy or suspected malignancy requiring further diagnostic evaluation. Active malignancy or suspected malignancy requiring further diagnostic evaluation. Active systemic inflammatory disease requiring anti-inflammatory or immunosuppressive treatment. Active systemic inflammatory disease requiring anti-inflammatory or immunosuppressive treatment. Autoimmune disease requiring systemic corticosteroids, immunosuppressive agents or biological therapy. Autoimmune disease requiring systemic corticosteroids, immunosuppressive agents or biological therapy. History of cardiovascular surgery. History of cardiovascular surgery. Severe renal insufficiency (creatinine clearance <30 mL/min) and/or chronic haemodialysis. Severe renal insufficiency (creatinine clearance <30 mL/min) and/or chronic haemodialysis. Known contraindication or previous severe intolerance to colchicine. Known contraindication or previous severe intolerance to colchicine. Pregnant or breastfeeding females. Pregnant or breastfeeding females. Clinically significant bone marrow suppression, defined as neutrophil count <1.5×109/L or platelet count <100×109/L. Clinically significant bone marrow suppression, defined as neutrophil count <1.5×109/L or platelet count <100×109/L. Intraaortic balloon pump, extracorporeal membrane oxygenation and other circulatory support before surgery. Intraaortic balloon pump, extracorporeal membrane oxygenation and other circulatory support before surgery. Patients with incomplete medical history information. Patients with incomplete medical history information. Who will take informed consent? Patients diagnosed with DCAD via coronary angiography will be screened for eligibility to participate in this study based on the aforementioned criteria. Following assessment by the attending physician confirming eligibility, patients will receive preliminary study information. After a minimum 3-day consideration period, patients will be invited to meet with the study physician to discuss the remaining questions and sign the ICF. No study procedures will be performed until consent is provided. Additional consent provisions for collection and use of participant data and biological specimens Individuals who choose to participate in the study will be asked to give permission for long-term monitoring of their electronic medical records (with no additional patient contact). Permission will be obtained to use study data in other ways. Blood samples and pericoronary fat tissue will be collected at Beijing Anzhen Hospital, affiliated with Capital Medical University. Biological samples and related data will only be collected and analysed after obtaining the patient’s written informed consent. Patient and public involvement statement This study was informed by insights from ongoing clinical engagement with patients diagnosed with complex coronary artery disease at Beijing Anzhen Hospital. Although this specific phase involving diagnostic data analysis did not include direct patient partnership, patient perspectives shared during care underscored the need for improved risk communication and personalised management, thereby shaping the research aims. A patient advisory group will be engaged in the subsequent phase to translate the imaging-derived risk models into practical decision aids and educational materials. All patient partners in this future work will receive remuneration for their time and expertise. Interventions Explanation for the choice of comparators The control group received standard secondary prevention therapy for coronary heart disease, including antiplatelet and lipid-lowering agents. The optimal oral medication regimen was jointly determined by three experienced associate physicians based on the 2024 ESC guidelines. Intervention description Standard procedure before randomisation Screening evaluations will have to be performed within 7 days before surgery. Preoperative data collection includes sex, age, body mass index, cardiovascular disease risk factors, left ventricular ejection fraction and left ventricular end-diastolic internal diameter. Lipid indices (including high-density lipoprotein cholesterol, low-density lipoprotein cholesterol and triglycerides), renal function indices (creatinine, creatinine clearance), fasting glucose, inflammation-related indices (IL-1, IL-6, tumour necrosis factor-alpha (TNF-α) and CRP) and troponin. Subsequently, the SYNTAX score of all coronary artery lesions will be collected using the SYNTAX score calculator (www.syntaxscore.com), which was used to evaluate coronary artery lesions. It is ensured that all preoperative patients undergo coronary CT angiography (CCTA), and the coronary artery calcium (CAC) score of all coronary lesions and the CAC score of all branch arteries were collected. 18F-NaF PET/CT images were acquired and analysed for all enrolled patients. Following a process of inclusion and exclusion, subjects will be randomly assigned to either the colchicine group or the control group. 18F-NaF PET/CT acquisition and image analysis All participants will undergo 18F-NaF PET/CT at baseline before CABG and again at 90 days after CABG. Baseline and follow-up PET/CT examinations will be performed using the same PET/CT scanner, and identical acquisition and reconstruction protocols will be used for both scans. Participants will be instructed to fast for at least 4 hours before imaging. Blood glucose will be measured before tracer administration for safety documentation; no specific glucose threshold is required for 18F-NaF PET/CT acquisition. A target dose of 18F-NaF of 3.7 MBq/kg will be administered intravenously. After tracer injection, participants will rest for 120 min in a quiet environment before image acquisition. ECG-gated cardiac PET/CT imaging will be acquired for 20 min using a Biograph mCT scanner (Siemens Medical Systems). A low-dose CT scan will be performed for attenuation correction using 120 kV and 50 mAs. PET image reconstruction will be performed using a point spread function plus time-of-flight algorithm (TrueX+time-of-flight, UltraHD-PET), with 5 iterations and 21 subsets. Owing to the small size of coronary plaques, an in-plane pixel size of 2 mm with a corresponding reconstructed image matrix size of 400×400 will be used to achieve high spatial resolution. Coronary 18F-NaF uptake will be quantified using the maximum standardised uptake value (SUVmax) within predefined three-dimensional regions of interest. Coronary regions of interest will be defined on coregistered CCTA and PET/CT images. The maximal localisation of coronary plaque uptake will be confirmed according to CCTA, 18F-NaF PET/CT images and CABG surgical records. The TBR will be calculated by correcting coronary plaque SUVmax for background blood pool activity. Background blood pool activity will be measured from the right atrium using standardised regions of interest at three consecutive levels, and the mean blood pool SUV will be used for TBR calculation. For the primary imaging endpoint, the same coronary segment or target lesion identified at baseline will be matched and reassessed on the 90-day PET/CT scan using CCTA anatomy, PET/CT fusion images and surgical records. The primary imaging endpoint will be analysed at the patient level using the maximum TBR of the prespecified target coronary segment or lesion. Native coronary segments corresponding to planned or completed bypass territories will be prioritised for analysis. Vessel-level and lesion-level TBR changes may be evaluated as exploratory imaging analyses. Segments with severe postoperative artefacts, inadequate image quality or inability to reliably match baseline and follow-up anatomy will be documented and handled according to the prespecified image analysis plan. All PET/CT images will be anonymised and coded before analysis. Image readers will be blinded to treatment allocation, clinical outcomes and medication records. Baseline and follow-up scans will be reviewed using prespecified analysis rules. Two experienced readers will independently assess coronary 18F-NaF uptake. Inter-reader reproducibility for TBR measurements will be assessed using the intraclass correlation coefficient. If substantial disagreement occurs, measurements will be reviewed jointly and resolved by consensus or by a third senior reader. Radiation exposure from baseline and 90-day PET/CT examinations will be estimated and documented for each participant. Low-dose CT protocols will be used when appropriate to minimise radiation exposure. The use of two PET/CT scans is justified by the mechanistic imaging objective of quantifying within-participant changes in coronary microcalcification activity, and the radiation burden has been considered during ethics review. Randomisation and intervention Randomisation will be performed only after all eligibility criteria have been confirmed, including preoperative 18F-NaF PET/CT showing TBR >3.6. Eligible participants will be randomised in a 1:1 ratio to the colchicine group or control group using stratified block randomisation. Stratification factors will include planned CABG strategy (off-pump vs on-pump) and a prespecified baseline TBR category. The colchicine group will receive colchicine tablets and optimal oral medication, and the control group will receive optimal oral medication on the basis of guidelines. Each patient will be assigned a medical record number on the basis of the date the informed consent form (ICF) was signed. A research assistant not involved in the study interventions and assessments will be responsible for randomisation. These randomisation sequences will be generated using Microsoft Excel software via block group randomisation with a length of 4 and will be managed by a research assistant who is not involved in the assessment or management of study patients. On receipt of the consent form by the assistant, patient demographics will be entered into the database, and the investigator and patient will be notified in writing of the treatment group to which the patient has been assigned. Figure 1 depicts the enrolment and randomisation procedures. Study design. CAC, coronary artery calcium; CABG, coronary artery bypass grafting; CAG, coronary angiography; CCTA, coronary CT angiography; [18F]NaF PET/CT, sodium [18F]fluoride positron emission tomography/CT; MACCEs, major adverse cardiovascular and cerebrovascular events; PMI, perioperative myocardial infarction; TBR, tissue-to-background ratio. Patients admitted for CABG will be given standard strategy before surgery. The colchicine group received 0.5 mg/day of colchicine and optimal oral medication starting 72 hours before surgery. The control group received optimal oral medication starting 72 hours before surgery. Low-dose colchicine and optimal oral medication regimens will be used until 90 days postoperatively. CABG will be performed through median sternotomy using either an on-pump or an off-pump grafting strategy according to surgeons’ experience. At the end of surgery, before protamine administration, graft flow and pulsatility index (PI) will be measured using the VeriQ Flowmeter System (MediStim ASA, Horten, Norway) based on transit-time flow measurement. A PI <5 will be considered acceptable. If PI is ≥5, the surgeon will reassess the graft and revise the anastomosis when clinically indicated. If PI remains ≥5 after technical revision and exclusion of reversible causes, graft dysfunction or incomplete revascularisation will be recorded as an intraoperative variable. These participants will remain in the intention-to-treat population. Such cases may be considered in prespecified per-protocol or sensitivity analyses but will not be excluded from the randomised cohort. Once the operation finishes, low-dose colchicine (0.5 mg/day) and optimal oral medication were given to patients in the colchicine group; optimal oral medication was given to patients in the control group. Insertion of a gastric tube for administration of medication when the patient is unable to take medication orally, such as with an invasive ventilator. Concomitant medication must be available in the source data and should be captured in the case report form (CRF) if necessary. The timeline of interventions is shown in figure 2. Timeline of interventions. The figure shows the planned time schedule for screening, randomisation, intervention, CABG, postoperative assessments, 18F-NaF PET/CT follow-up and clinical outcome collection in the COL-CABG trial. CABG, coronary artery bypass grafting; 18F-NaF PET/CT, sodium [18F]fluoride positron emission tomography/CT; MACCEs, major adverse cardiovascular and cerebrovascular events; PMI, perioperative myocardial infarction; TBR, tissue-to-background ratio. Criteria for discontinuing or modifying allocated interventions Patients can leave the study at any time for any reason if they wish to do so without any consequences. Participation in this study can also be ended by the investigator if the patient is uncooperative and/or does not attend study visits. The patient data that have been collected up to that moment will be included in the analysis. Participants who withdraw from the intervention or have incomplete follow-up data will not be replaced after randomisation. All randomised participants will remain in the intention-to-treat population, and missing data will be handled according to the prespecified statistical analysis plan. This study will be prematurely ended in case of any increase in adverse events or compound-related complications. Criteria for study termination include any suspected unexpected serious adverse event (SAE). In case of premature ending, all included patients will be informed by their treating surgeon. In case of illness, patients will be asked to contact the primary investigator. Colchicine may be temporarily interrupted or permanently discontinued if participants develop severe diarrhoea or persistent gastrointestinal intolerance, clinically significant cytopenia, acute kidney injury, severe hepatic dysfunction, sepsis, serious infection, severe wound complication or other adverse events judged by the investigator to be clinically relevant. Colchicine will also be interrupted or avoided when participants require concomitant strong CYP3A4 or P-glycoprotein inhibitors, including macrolide antibiotics or azole antifungal agents. All treatment interruptions, discontinuations and reasons will be documented in the electronic CRF (eCRF). Strategies to improve adherence to interventions Three strategies for improving subject adherence to the intervention will be implemented. First, a portion of the individuals’ healthcare and travel expenditures will be reimbursed. Second, physicians will offer free consultations. Finally, the researchers will communicate with the subjects at least once a week. Relevant concomitant care permitted or prohibited during the trial Implement standard secondary prevention measures for coronary heart disease preoperatively. Record postoperative bleeding volume. If <50 mL/hour, administer intravenous heparin for thrombus prevention at 4 hours postoperatively. All patients received aspirin 100 mg/day and clopidogrel 75 mg/day starting on postoperative day 1. If PMI occurred, add low molecular weight heparin 60 mg every 12 hours to the dual antiplatelet regimen. All enrolled patients received statin therapy with a target LDL <1.44 mmol/L. LDL levels were rechecked 2 weeks postoperatively. If the target is not met, ezetimibe or a proprotein convertase subtilisin/kexin type 9 inhibitor will be added. LDL levels will be rechecked 2 weeks after dose adjustment until LDL <1.44 mmol/L is achieved. Postoperative target heart rate of 50–70 beats per minute will be maintained using beta-blockers. All patients will receive oral proton pump inhibitor therapy. Blood pressure and blood glucose are controlled symptomatically within normal ranges. All episodes of care will be recorded in an eCRF. Concomitant medications will be reviewed throughout the trial to identify potential drug interactions with colchicine. Strong cytochrome P450 3A4 (CYP3A4) or P-glycoprotein inhibitors, including macrolide antibiotics and azole antifungal agents, should be avoided whenever possible during colchicine treatment. If such medications are clinically necessary, colchicine will be temporarily interrupted or discontinued according to the investigator’s assessment. Provisions for post-trial care There are no provisions for post-trial care since the interventions are found to be feasible and safe in this population and the study is situated in routine clinical practice. Usual care will continue when the trial ends. Outcomes The primary endpoint is defined as the changes in coronary microcalcification activity (ΔTBR=TBR (baseline)–TBR (90 days)) at 90 days after CABG in comparison with the pre-CABG; a larger positive ΔTBR indicates a greater reduction in coronary microcalcification activity and therefore represents a favourable imaging response. Secondary clinical outcomes include PMI within 7 days after CABG and MACCEs within 90 days after CABG. PMI will be defined as CABG-related myocardial infarction occurring within 7 days after surgery according to prespecified biomarker, electrocardiographic, imaging and angiographic criteria. Spontaneous myocardial infarction occurring after postoperative day 7 and within 90 days after CABG will be classified as new myocardial infarction within MACCEs. MACCEs will include all-cause death, cardiogenic shock, spontaneous myocardial infarction occurring after postoperative day 7, stroke and repeat coronary revascularisation. To avoid double counting, CABG-related PMI occurring within 7 days after surgery will not be counted again as a new myocardial infarction within MACCEs. These clinical endpoints will be analysed as exploratory and hypothesis-generating outcomes because the trial is powered for the imaging endpoint rather than for clinical events. MACCEs within 1 year after CABG will be collected as an exploratory long-term clinical outcome. Definitions TBR can reflect the degree of coronary artery microcalcification. It is calculated using the following equation: SUVmax signifies the maximal SUV of 18F-NaF, while SUVmean denotes the average SUV of blood in the lumen of the right atrium at three consecutive levels for the mean SUV of blood in the right atrium lumen from the same bed. PMI is defined as an increase in baseline cardiac troponin (cTn) of >10 times the upper limit of 99% of the normal reference value within 7 days postoperatively. For patients with a stable (<20%) increase or decrease in cTn levels prior to CABG, the cTn must have risen by >20% postoperatively and must still be >10 times the upper limit of 99% of the normal reference value. Furthermore, the fulfilment of one of the following conditions is requisite. The presence of new ischaemic changes on ECG is the primary diagnostic criterion. The identification of new pathogenic Q waves on ECG is also a diagnostic indicator. The loss of surviving myocardium or presence of segmental ventricular wall motion abnormalities, confirmed by ECG, is a further diagnostic indicator. New bridging vessel occlusion or self-coronary artery occlusion, demonstrated by coronary angiography or CCTA, is the final diagnostic indicator. Cardiogenic shock is defined as an acute failure of the heart’s pump function, resulting in a significant decrease in cardiac output, which is unable to meet the perfusion demands of peripheral tissues and triggers a clinical syndrome of progressive organ hypoperfusion and hypoxia. All-cause mortality is defined as the death of a patient from any cause in the postoperative period. Stroke encompasses two distinct categories: ischaemic and haemorrhagic. Ischaemic stroke is defined as the presence of new symptoms or the exacerbation of existing symptoms (as indicated by an increase in the National Institutes of Health Stroke Scale (NIHSS) score by four points or more), with a duration exceeding 24 hours, which constitutes the initial criterion. The subsequent criterion involves the emergence of new symptoms or the exacerbation of existing symptoms (as indicated by an increase in the NIHSS score by four points or more), with a duration of less than 24 hours, and the confirmation of new infarcted foci or the enlargement of existing infarcted foci through imaging (CT or MRI). The elimination of etiologic factors such as fever, drug effects and infections is imperative in both cases. Haemorrhagic stroke is used to describe acute focal or total brain or spinal cord neurologic dysfunction caused by nontraumatic intraparenchymal, intraventricular or subarachnoid haemorrhage. Repeat coronary revascularisation is defined as postprocedural reperfusion percutaneous coronary intervention or CABG. Participant timeline The participant timeline is shown in table 1. Table 1Schedule of enrolment, interventions and assessmentsStudy periodEnrollmentAllocationPostallocationCloseoutTimepoint−72 hours07 days90 days1 year Enrollment X Eligibility screen X Informed consent X Allocation X Interventions Colchicine Optimal oral medication Assessments 18F-NaF PET/CT X X CAG X CCTA X X Medical history X Routine blood tests X X X ECG X X X X UCG X X X Chest X-ray or CT X X X PMI X MACCEs X X X CAG, coronary angiography; CCTA, coronary CT angiography; 18F-NaF PET/CT, sodium [18F]fluoride; MACCEs, major adverse cardiovascular and cerebrovascular events; PMI, perioperative myocardial infarction; UCG, echocardiography. Schedule of enrolment, interventions and assessments CAG, coronary angiography; CCTA, coronary CT angiography; 18F-NaF PET/CT, sodium [18F]fluoride; MACCEs, major adverse cardiovascular and cerebrovascular events; PMI, perioperative myocardial infarction; UCG, echocardiography. Sample size Sample size was calculated using PASS V.2024 software. Based on the mean coronary TBR of 4.38 in the cardiovascular event group from published articles, and considering the improvement in 90-day coronary microcalcification activity in coronary bypass graft patients treated with low-dose colchicine,3 the following hypotheses were established. The treatment group is projected to achieve a 30% reduction (1.31) in coronary microcalcification activity at 90 days, while the control group is expected to achieve a 15% reduction (0.66). With an SD of 1 for the change magnitude, a two-tailed test (α=0.05) was applied, with 90% statistical power. The calculated sample size was 102 cases. Considering that 5% of patients may experience severe gastrointestinal side effects from colchicine and withdraw from the trial, the final required sample size was 108 cases, with 54 cases in each group. Recruitment Over the past 3 years, Beijing Anzhen Hospital has performed an average of over 5000 coronary artery bypass graft surgeries annually and conducted approximately 400 cardiac PET/CT scans. The required number of participants can be achieved. Assignment of interventions: allocation Sequence generation Randomisation will be performed only after written informed consent has been obtained and all eligibility criteria have been confirmed, including preoperative 18F-NaF PET/CT showing TBR >3.6. Eligible participants will be randomised in a 1:1 ratio to the colchicine group or control group using stratified block randomisation. Stratification factors will include planned CABG strategy (off-pump vs on-pump) and a prespecified baseline TBR category. The randomisation sequence will be generated by an independent research assistant who is not involved in participant recruitment, intervention delivery, outcome assessment or statistical analysis. Concealment mechanism Allocation will be concealed before assignment using sequentially numbered, opaque, sealed envelopes prepared and kept by an independent research assistant who is not involved in participant recruitment, intervention delivery, outcome assessment or statistical analysis. Treatment allocation will be revealed only after written informed consent has been obtained and all eligibility criteria have been confirmed, including preoperative 18F-NaF PET/CT showing TBR >3.6. The trial is open-label after randomisation for participants and treating clinicians, but endpoint assessment and statistical analysis will remain blinded. Implementation After written informed consent has been obtained and all eligibility criteria have been confirmed, the independent research assistant will assign the participant according to the concealed randomisation sequence. The participant and treating clinicians will then be informed of the allocated treatment group. Outcome assessors, imaging readers, clinical endpoint adjudicators and statisticians will not have access to treatment allocation before database lock and completion of the primary analysis. Assignment of interventions: blinding Who will be blinded Treatment allocation will be open-label for participants and treating clinicians after randomisation. PET/CT imaging readers, clinical endpoint adjudicators and statisticians will be blinded to treatment allocation. Blinding will be made possible through: (a) assessing outcomes via a data collection platform; (b) restricting access to participants’ treatment assignments in the study database only to staff whose role is to contact participants before and throughout the intervention phase. PET/CT images will be anonymised and coded before analysis. All treatment-related information, including use of colchicine, will be removed from the imaging dataset. Imaging readers will not have access to treatment allocation, clinical outcome data or medication records. Clinical endpoint adjudicators will receive prespecified source documents without treatment allocation. Statisticians will analyse the locked database using masked group labels until the primary analysis is completed. Procedure for unblinding if needed Because treatment allocation is open-label for participants and treating clinicians, emergency unblinding for clinical management is not applicable. Imaging readers, clinical endpoint adjudicators and statisticians will remain blinded until database lock and completion of the primary analysis. If access to treatment allocation is required for participant safety, regulatory reporting or investigation of an SAE, unblinding of blinded assessors may be authorised by the principal investigator and will be documented in the trial record. Data collection and management Plans for assessment and collection of outcomes Data will be collected using a study-specific CRF. Throughout the trial, data management personnel will validate the data. Data fields will be checked, and any missing data or inconsistencies will be corrected before downloading into the study database. All identifying information will be hidden to protect patient confidentiality. All study personnel will have 24-hour access to the study coordinating centre. A data monitoring committee will monitor data accuracy and completeness, evaluate adverse events and make the final decision to terminate the trial. When all data management and statistical data validation procedures have been completed, the database will be unlocked to perform the final analysis. Plans to promote participant retention and complete follow-up The patients will receive extensive information about the study set-up and requirements during the recruitment. The importance of completing the follow-up will be stressed. Patients are allowed to stop at any time during the study and are not obliged to give a reason to discontinue. If possible, the patient will be asked to complete the online survey 30 days after CABG. Questionnaires are completed using an online survey, and therefore patients can do this at any convenient moment. All patients are reminded throughout the study to fill out the questionnaires during study visits. Data management A clinical database for DCAD patients was established, with all clinical data collected from the electronic medical record system of Beijing Anzhen Hospital. Participants will undergo regular postoperative follow-up for up to 1 year after CABG to collect exploratory long-term clinical outcomes, including MACCEs. All included clinical indicators were defined according to corresponding guidelines or authoritative literature. The database was independently established by a third party and managed by at least two dedicated personnel. Data will undergo double verification to ensure data authenticity and completeness. Missing or inconsistent data will be queried and resolved where possible according to the data management plan. Participants with incomplete data will not be excluded from the intention-to-treat population solely because of missing data. The system provides both automated data queries and manual data queries. Data administrators will conduct daily, case-by-case verification of uploaded data. During this process, any data concerns should trigger manual queries sent to the investigator. Data administrators are experienced physicians from the Cardiac Surgery Centre at Beijing Anzhen Hospital. All queries must be logged in a detailed system record, including query content, originator, date raised and resolution date. Confidentiality Only the lead investigator and necessary staff will have access to collected data. To protect patient confidentiality, each subject’s laboratory samples, completed forms, reports and other data will be identified by a special participant ID number. Plans for collection, laboratory evaluation and storage of biological specimens for genetic or molecular analysis in this trial/future use Blood samples and pericoronary fat tissue will be collected at Beijing Anzhen Hospital, affiliated with Capital Medical University. Biological samples and related data will only be collected and analysed after obtaining the patient’s written informed consent. After project termination, samples and data will be safely stored for 5 years and then disposed of. Their future use in ancillary studies is not yet planned. Statistical methods Statistical methods for primary and secondary outcomes The statistical analysis plan has been reviewed by an independent biostatistician. Statistical analyses will be performed using SPSS V.23.0 or equivalent statistical software. Continuous variables will be summarised as mean±SD deviation or median with IQR, as appropriate. Categorical variables will be summarised as frequencies and percentages. All statistical tests for the primary endpoint will be two-sided, and a p value<0.05 will be considered statistically significant. The primary analysis will be conducted in the intention-to-treat population, defined as all randomised participants. The primary endpoint is the absolute change in coronary microcalcification activity from baseline to 90 days after CABG, calculated as ΔTBR=TBR (baseline) − TBR (90 days). A larger positive ΔTBR indicates a greater reduction in coronary microcalcification activity and therefore represents a favourable imaging response. The primary treatment effect will be estimated using analysis of covariance, with 90-day TBR as the dependent variable, treatment group as the main independent variable and baseline TBR as a prespecified covariate. The adjusted between-group mean difference will be reported with 95% CIs and corresponding p values. As a sensitivity analysis, ΔTBR will also be compared between groups using a linear regression model adjusted for baseline TBR. Baseline characteristics will be compared descriptively between treatment groups. Continuous variables will be compared using the independent-samples t-test or Mann-Whitney U test, as appropriate. Categorical variables will be compared using the χ² test or Fisher’s exact test, as appropriate. These comparisons will be interpreted descriptively and will not be used to determine the success of randomisation. Secondary clinical outcomes, including PMI within 7 days after CABG and MACCEs within 90 days after CABG, will be analysed as exploratory and hypothesis-generating outcomes because the trial is powered for the imaging endpoint rather than for clinical events. Binary clinical outcomes will be summarised using risk ratios or ORs with 95% CIs. Time-to-event outcomes, including exploratory 1-year MACCEs, will be summarised using Kaplan-Meier curves and Cox proportional hazards models when appropriate. HRs with 95% CIs will be reported. Exploratory analyses will assess changes in inflammatory biomarkers, including IL-1, IL-6, TNF-α and CRP, from baseline to follow-up. Associations between changes in inflammatory biomarkers and changes in TBR may be evaluated using correlation analysis and multivariable regression models, as appropriate. These exploratory analyses will be interpreted cautiously and will not be considered confirmatory. A per-protocol analysis will be performed as a sensitivity analysis for the primary endpoint, excluding participants with major protocol deviations, such as failure to receive the allocated intervention, major violations of eligibility criteria or absence of the 90-day PET/CT assessment unrelated to death or severe clinical deterioration. The safety population will include all participants who receive at least one dose of colchicine or standard medical therapy after randomisation. Missing data will be summarised according to the amount and reason for missingness. For the primary endpoint, multiple imputation will be considered if the proportion of missing 90-day TBR data is substantial and the missing-at-random assumption is considered reasonable. Complete-case analysis will also be performed as a sensitivity analysis. Participants who die before the 90-day PET/CT assessment will remain in the intention-to-treat population, and missing imaging data due to death or severe clinical deterioration will be addressed in sensitivity analyses. No formal interim efficacy analysis is planned because of the modest sample size and short-term imaging primary endpoint. Safety data will be reviewed periodically by the trial steering committee or data and safety monitoring committee throughout the study. Interim analyses No formal interim efficacy analysis is planned because the trial has a modest sample size and a short-term imaging primary endpoint. Safety data, recruitment progress, protocol adherence and data completeness will be reviewed periodically by the trial steering committee or data and safety monitoring committee, at least every 6 months during recruitment. Methods for additional analyses (eg, subgroup analyses) Exploratory analyses will include changes in inflammatory biomarkers, including IL-1, IL-6, TNF-α and CRP, from baseline to follow-up, as well as exploratory 1-year MACCEs. Vessel-level and lesion-level changes in TBR may also be evaluated as exploratory imaging outcomes. These analyses will be interpreted as hypothesis-generating and will not be considered confirmatory. Methods in analysis to handle protocol non-adherence and any statistical methods to handle missing data Protocol deviations will be classified as major or minor before database lock and, where feasible, while blinded to treatment allocation. The primary analysis will follow the intention-to-treat principle and will include all randomised participants. A per-protocol analysis excluding participants with major protocol deviations will be performed as a sensitivity analysis for the primary imaging endpoint. Missing data will be summarised according to the amount and reason for missingness. For missing 90-day TBR data, multiple imputation will be considered if the missing-at-random assumption is reasonable, and complete-case analysis will be performed as a sensitivity analysis. Participants who die or experience severe clinical deterioration before the 90-day PET/CT assessment will remain in the intention-to-treat population, and such missing imaging data will be addressed in prespecified sensitivity analyses. Plans to give access to the full protocol, participant-level data and statistical code The corresponding author will provide trial datasets and algorithms on reasonable request. Oversight and monitoring Composition of the coordinating centre and trial steering committee This is a single-centre study designed, performed and coordinated at Beijing Anzhen Hospital; the study team meets biweekly. Day-to-day support for the trial is provided by: Principal investigator: supervises the trial and has medical responsibility for the patients. Principal investigator: supervises the trial and has medical responsibility for the patients. Data manager: organises data capture, safeguards quality and data. Data manager: organises data capture, safeguards quality and data. Study coordinator: trial registration, coordinates study visits and annual safety reports. Study coordinator: trial registration, coordinates study visits and annual safety reports. Study physician: identifies recruits, takes informed consent and ensures follow-up according to protocol. Study physician: identifies recruits, takes informed consent and ensures follow-up according to protocol. PET/CT quality control technician: image quality control. PET/CT quality control technician: image quality control. Composition of the data monitoring committee, its role and reporting structure A Data and Safety Monitoring Committee has been established for this trial. The committee will review recruitment progress, protocol adherence, data completeness and adverse events at regular intervals. SAEs will be reviewed in a timely manner, and the committee may recommend protocol modifications or trial termination if participant safety is compromised. Adverse event reporting and harms Although low-dose colchicine has been used in patients with chronic coronary syndromes, perioperative CABG patients may be vulnerable to renal dysfunction, hepatic dysfunction, cytopenia, infection, wound complications, gastrointestinal intolerance and drug interactions. Therefore, safety will be actively monitored throughout the trial. Safety assessments will include renal function, hepatic function, complete blood counts, gastrointestinal symptoms, infection, wound healing and concomitant medications. These assessments will be performed during hospitalisation and at scheduled follow-up visits, and additional assessments will be performed when clinically indicated. Colchicine may be temporarily interrupted or permanently discontinued if participants develop severe diarrhoea or persistent gastrointestinal intolerance, clinically significant cytopenia, acute kidney injury, severe hepatic dysfunction, sepsis, serious infection, severe wound complication or other adverse events judged by the investigator to be clinically relevant. Colchicine will also be interrupted or avoided when participants require concomitant strong CYP3A4 or P-glycoprotein inhibitors, including macrolide antibiotics or azole antifungal agents. All treatment interruptions, discontinuations and reasons will be documented in the eCRF. If an SAE occurs, complete information regarding the SAE, including the nature of the event, start and end dates, severity, relationship to the trial intervention or procedures, and outcome, will be recorded in the medical record and eCRF within 24 hours of occurrence. Such incidents will be followed until satisfactorily resolved or stabilised. The site team and principal investigator will determine the relatedness and expectedness of each SAE. Relevant unexpected SAEs will be reported to the sponsor and ethics committee according to regulatory requirements. The study data centre will provide an eCRF for central collection of adverse events and SAEs, and safety reports will be submitted to the trial steering committee or Data and Safety Monitoring Committee at regular intervals until study completion. Frequency and plans for auditing trial conduct An audit of all entries into the eCRF and the number of participants will be conducted annually. Plans for communicating important protocol amendments to relevant parties (eg, trial participants, ethical committees) Any protocol amendments will be authorised by the ethics committee before being implemented and updated in the ChiCTR.org registration. All investigators and study participants will be informed. Deviations from the protocol will be thoroughly documented using a report form. Dissemination plans The findings of the study will be communicated largely through patient timelines and public forums, conference presentations and scientific articles. The final manuscript will be reviewed and approved by all writers. Discussion Hypotheses and possible trial outcomes The COL-CABG trial is a prospective, single-centre, randomised, open-label, blinded-endpoint trial designed to evaluate whether low-dose colchicine reduces coronary microcalcification activity after CABG in patients with DCAD. In this PROBE design, treatment allocation is open-label for participants and treating clinicians, whereas PET/CT imaging outcomes, clinical endpoints and statistical analyses are assessed by investigators blinded to treatment allocation. The primary endpoint of this trial is the change in coronary microcalcification activity from baseline to 90 days after CABG, as quantified by 18F-NaF PET/CT. The 90-day time point was selected because the primary objective of this study is to evaluate early mechanistic changes in coronary microcalcification activity after initiation of low-dose colchicine in the perioperative CABG setting. 18F-NaF uptake reflects active microcalcification and plaque biological activity, which may change earlier than long-term clinical outcomes. Therefore, the 90-day PET/CT assessment is intended to provide mechanistic imaging evidence rather than definitive evidence of clinical event reduction. We acknowledge that 90 days may be insufficient to determine whether colchicine reduces long-term MACCEs. Accordingly, PMI within 7 days and MACCEs within 90 days after CABG will be interpreted as exploratory and hypothesis-generating clinical outcomes. MACCEs within 1 year after CABG will also be collected as an exploratory long-term clinical outcome. The interpretation of changes in 18F-NaF uptake after CABG requires caution. A reduction in TBR may reflect the biological effect of colchicine on coronary inflammation and microcalcification activity, but it may also be influenced by CABG-related changes in coronary haemodynamics, intensive secondary prevention therapy, postoperative inflammatory responses, image measurement variability and regression to the mean. Therefore, the imaging results will be interpreted together with changes in inflammatory biomarkers, clinical outcomes and prespecified sensitivity analyses. Ethics and dissemination The COL-CABG trial has been approved by the Ethics Committee of Beijing Anzhen Hospital, Capital Medical University (approval number: 2025202x). The study will be conducted in accordance with the Declaration of Helsinki and relevant national regulations for clinical research. Written informed consent will be obtained from all participants before any study-specific procedures are performed. Participant confidentiality will be protected throughout the trial. Each participant will be assigned a unique study identification number, and identifiable information will be stored separately from study data. Only authorised members of the study team will have access to identifiable information and the final dataset. Biological samples and related data will be collected and analysed only after written informed consent has been obtained. The findings of this trial will be disseminated through peer-reviewed scientific publications and presentations at national and international conferences. A template participant ICF will be provided as online supplemental files. Trial status Recruitment is scheduled to begin on 1 July 2026 and is planned to be completed by 30 June 2028. Current protocol: V.2 of 6-21-2026. Supplementary material